Acorda And Elan To Develop Fampridine
Acorda Therapeutics of New York has signed an agreement with Ireland'sElan to develop Elan's oral, sustained-release formulation of fampridine (4-aminopyridine) for the treatment of spinal cord injury. SCI is currently only treated with high-dose steroids.
Fampridine has been found to increase the ability of damaged nerve axons to conduct electrical impulses, and in initial human studies, the drug has achieved encouraging results in patients with spinal cord injury and multiple sclerosis. Acorda has worldwide rights to the formulation for SCI, while Elan retains rights for MS and other applications.
Fampridine acts by blocking specialized potassium channels, which become exposed when the insulating myelin sheath around axons is damaged.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze